A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

A new type of CAR T-cell therapy elicits a more controlled immune response to cancer in mice, effectively killing cancer ...

Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...